Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice

J Kassa, J Karasova, K Musilek, K Kuca

. 2008 ; 243 (3) : 311-316.

Jazyk angličtina Země Irsko

Typ dokumentu srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc11003249

The potency of newly developed monoxime bispyridinium compounds (K156, K203) in reactivating tabun-inhibited acetylcholinesterase and reducing tabun-induced lethal toxic effects was compared with commonly used oximes (obidoxime, trimedoxime, the oxime HI-6) using in vivo methods. Studies determining percentage of reactivation of tabun-inhibited blood and tissue acetylcholinesterase in poisoned rats showed that the reactivating efficacy of newly developed oxime K203 is comparable with obidoxime and trimedoxime in blood and higher than the reactivating potency of trimedoxime and obidoxime in diaphragm and brain, where the difference in reactivating efficacy of obidoxime, trimedoxime and K203 is significant. On the other hand, the potency of newly developed K156 to reactivate tabun-inhibited acetylcholinesterase is comparable with obidoxime or trimedoxime in diaphragm and brain. It is significantly lower than the reactivating efficacy of trimedoxime and obidoxime in blood. Moreover, both newly developed oximes were found to be relatively efficacious in the reduction of lethal toxic effects in tabun-poisoned mice. Especially, the oxime K203 is able to decrease the acute toxicity of tabun nearly two times. The therapeutic efficacy of K156 and K203 corresponds to their potency to reactivate tabun-inhibited acetylcholinesterase, especially in diaphragm and brain. In contrast to obidoxime and trimedoxime, the oxime HI-6 is not effective in reactivation of tabun-inhibited acetycholinesterase and in reducing tabun lethality. While the oxime K156 does not improve the reactivating and therapeutic effectiveness of currently available obidoxime and trimedoxime, the newly developed oxime K203 is markedly more effective in reactivation of tabun-inhibited acetylcholinesterase in rats, especially in brain, and in reducing lethal toxic effects of tabun in mice and, therefore, it is suitable for the replacement of commonly used oximes for the antidotal treatment of acute tabun poisoning.

Citace poskytuje Crossref.org

000      
05205naa 2200769 a 4500
001      
bmc11003249
003      
CZ-PrNML
005      
20111210202249.0
008      
110225s2008 ie e eng||
009      
AR
024    __
$a 10.1016/j.tox.2007.10.015 $2 doi
035    __
$a (PubMed)18054821
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Kassa, Jiří, $d 1956- $7 mzk2003181395
245    13
$a An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice / $c J Kassa, J Karasova, K Musilek, K Kuca
314    __
$a Department of Toxicology, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. kassa@pmfhk.cz
520    9_
$a The potency of newly developed monoxime bispyridinium compounds (K156, K203) in reactivating tabun-inhibited acetylcholinesterase and reducing tabun-induced lethal toxic effects was compared with commonly used oximes (obidoxime, trimedoxime, the oxime HI-6) using in vivo methods. Studies determining percentage of reactivation of tabun-inhibited blood and tissue acetylcholinesterase in poisoned rats showed that the reactivating efficacy of newly developed oxime K203 is comparable with obidoxime and trimedoxime in blood and higher than the reactivating potency of trimedoxime and obidoxime in diaphragm and brain, where the difference in reactivating efficacy of obidoxime, trimedoxime and K203 is significant. On the other hand, the potency of newly developed K156 to reactivate tabun-inhibited acetylcholinesterase is comparable with obidoxime or trimedoxime in diaphragm and brain. It is significantly lower than the reactivating efficacy of trimedoxime and obidoxime in blood. Moreover, both newly developed oximes were found to be relatively efficacious in the reduction of lethal toxic effects in tabun-poisoned mice. Especially, the oxime K203 is able to decrease the acute toxicity of tabun nearly two times. The therapeutic efficacy of K156 and K203 corresponds to their potency to reactivate tabun-inhibited acetylcholinesterase, especially in diaphragm and brain. In contrast to obidoxime and trimedoxime, the oxime HI-6 is not effective in reactivation of tabun-inhibited acetycholinesterase and in reducing tabun lethality. While the oxime K156 does not improve the reactivating and therapeutic effectiveness of currently available obidoxime and trimedoxime, the newly developed oxime K203 is markedly more effective in reactivation of tabun-inhibited acetylcholinesterase in rats, especially in brain, and in reducing lethal toxic effects of tabun in mice and, therefore, it is suitable for the replacement of commonly used oximes for the antidotal treatment of acute tabun poisoning.
650    _2
$a acetylcholinesterasa $x krev $x metabolismus $7 D000110
650    _2
$a testy akutní toxicity $x metody $7 D023382
650    _2
$a zvířata $7 D000818
650    _2
$a antidota $x aplikace a dávkování $x chemie $x terapeutické užití $7 D000931
650    _2
$a atropin $x aplikace a dávkování $x chemie $x terapeutické užití $7 D001285
650    _2
$a cholinesterasové inhibitory $x aplikace a dávkování $x chemie $x otrava $7 D002800
650    _2
$a reaktivátory cholinesterasy $x aplikace a dávkování $x chemie $x terapeutické užití $7 D002801
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a injekce intramuskulární $7 D007273
650    _2
$a LD50 $7 D007928
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a molekulární struktura $7 D015394
650    _2
$a obidoxim chlorid $x aplikace a dávkování $x chemie $x terapeutické užití $7 D009768
650    _2
$a oximy $x aplikace a dávkování $x chemie $x terapeutické užití $7 D010091
650    _2
$a organofosfáty $x aplikace a dávkování $x chemie $7 D010755
650    _2
$a pyridinové sloučeniny $x aplikace a dávkování $x chemie $x terapeutické užití $7 D011726
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a záchvaty $x enzymologie $x chemicky indukované $x prevence a kontrola $7 D012640
650    _2
$a druhová specificita $7 D013045
650    _2
$a trimedoxim $x aplikace a dávkování $x chemie $x terapeutické užití $7 D014289
650    _2
$a financování organizované $7 D005381
650    _2
$a otrava organofosfáty $7 D062025
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Žďárová Karasová, Jana, $d 1982- $7 xx0099787
700    1_
$a Musílek, Kamil, $d 1980- $7 xx0135628
700    1_
$a Kuča, Kamil, $d 1978- $7 xx0041831
773    0_
$t Toxicology $w MED00004533 $g Roč. 243, č. 3 (2008), s. 311-316 $x 0300-483X
910    __
$a ABA008 $b x $y 7
990    __
$a 20110413115713 $b ABA008
991    __
$a 20110413115713 $b ABA008
999    __
$a ok $b bmc $g 830602 $s 695242
BAS    __
$a 3
BMC    __
$a 2008 $b 243 $c 3 $d 311-316 $i 0300-483X $m Toxicology $n Toxicology $x MED00004533
LZP    __
$a 2011-2B/ipme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...